This study sought to identify genital tract characteristics associated with vertical transmission of human immunodeficiency virus type 1 (HIV-1). HIV-1 DNA and RNA, HIV-1 env diversity, and inflammatory cells were quantified in cervicovaginal lavages (CVLs) of 24 women enrolled in the Women and Infants Transmission Study; 7 women transmitted HIV-1 perinatally. Vaginal candidiasis, HIV-1 culture positivity, levels of HIV-1 DNA and cell-free RNA, and HIV-1 env diversity were significantly higher in the CVLs of transmitters. CVL HIV-1 DNA levels correlated with higher levels of inflammatory cells and cell-free HIV-1 RNA. Of subjects with paired blood and CVL specimens, there was more HIV-1 env heterogeneity between blood and CVLs in transmitters than in nontransmitters. In summary, increased HIV-1 shedding is correlated with a more complex population of HIV-1 quasispecies in the genital tracts of parturient women, which may increase the probability that a fetotropic strain is transmitted.
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in changes of the env glycoprotein [14, 15] and single amino acid substitutions sometimes causing a change in cellular tropism [16] . As opposed to cloning and genetic sequencing, the use of the heteroduplex tracking assay (HTA) allows rapid assessment of qualitative genetic differences within and between samples. When a diverse population of HIV-1 env genes is amplified by polymerase chain reaction (PCR) and heteroduplexes between nonidentical DNA strands are forced to form, the more slowly migrating heteroduplexes on gel electrophoresis indicate the presence and extent of genetic diversity in the sample [17, 18] . In this study, we used HTA to characterize the relationship between the extent of HIV-1 cell-associated env heterogeneity in the peripartum cervicovaginal lavages (CVLs) of HIV-positive women in relation to genital tract virus load, inflammation as measured by numbers of polymorphonuclear cells (PMNL) and macrophages, and perinatal HIV-1 transmission.
Patients and Methods
Patients. We studied a subset of pregnant women participating in the Boston Women and Infants Transmission Study (WITS), a multisite long-term epidemiologic study of HIV-infected pregnant women and their infants [7] . We included women who had live births and an available CVL sample collected at weeks of 34 ‫ע‬ 4 gestation. "Perinatal transmission" was defined as the infant's having HIV-1 isolated in у2 separate blood cultures obtained within the first 6 months of life. Infants having у2 HIV-negative blood cultures у1 month apart (with the last culture у6 months after delivery) were viewed as uninfected [19] . All women received oral zidovudine prior to delivery and/or intravenous zidovudine at delivery. Demographic data were abstracted from study charts.
CVL sample processing and culture. CVLs were obtained from women during speculum examination by gentle lavage of the endocervical os and exocervix with 10 mL of sterile saline and collection of the entire lavage solution. Specimens were immediately placed on ice, delivered to the laboratory, and processed within 30 min. Each CVL was evaluated for numbers of PMNL and macrophages, as described elsewhere [20] . After centrifugation, cellular pellets of CVL cells were stored at Ϫ70ЊC as dry pellets 6 1-5 ϫ 10 for DNA analysis, and both cellular and cell-free (250 mL of CVL supernatant) aliquots were stored at Ϫ70ЊC in 750 mL of Tri reagent (Molecular Research Center, Cincinnati) for RNA analysis. Half of the fresh cellular and cell-free components were cultured for HIV-1 according to a modified microculture protocol [21] . In brief, CVL supernatant was concentrated 7ϫ by centrifugation (Centriprep-50; Amicon, Beverly, MA) for 10 min, and 500 mL of concentrate was placed into culture with phytohemagglutinin- 6 4 ϫ 10 activated peripheral blood mononuclear cells (PBMC). CVL cells were resuspended in processing medium containing 80% RPMI 1640, 20% normal human serum type AB (Scantibodies Laboratory, Santee, CA), 10 mmol HEPES (Sigma, St. Louis), 2 mmol Lglutamine, 50 U/mL penicillin, 50 mg/mL streptomycin, and 0.125 mg/mL amphotericin-B (Gibco, Grand Island, NY). The samples were kept on ice in this solution for 20 min, then placed into culture with PBMC. Within 12 h of plating, the cells were washed 6 4 ϫ 10 to remove residual antimycotic. Cultures were maintained for 28 days and were fed medium twice weekly and PBMC once weekly. Culture supernatants were assayed every 7 days for p24 antigen over 28 days.
PBMC culture and processing. Quantitative PBMC cultures for HIV-1 were done as previously described [22] . In 5 patients, PBMC pellets from blood drawn at the time of CVL sample acquisition were available for PCR. These aliquots of 6 0.5-2 ϫ 10 PBMC were washed with PBS and stored at Ϫ70ЊC for PCR analysis.
CVL quantitative PCR. PCR and reverse-transcription (RT) PCR were performed on aliquots of cellular and cell-free components of CVL samples, and the PCR product was quantitated by an ELISA, as described elsewhere [23] . Quantitative DNA PCR was performed on batched samples of dry CVL cell pellets with controls of HIV-negative CVL cell pellets alone or spiked with 10, 100, or 1000 8E5 human T lymphocytes containing 1 HIV-1 copy per cell (NIH AIDS Repository, Rockville, MD). The samples were thawed to room temperature and incubated on a rotator at 50ЊC for 60 min in 500 mL of a lysis buffer containing 10 mM Tris-HCl (pH 8.0), 10 mM EDTA, 50 mM NaCl, 2% SDS, and 300 mg/mL proteinase K (Boehringer Mannheim, Indianapolis). DNA was extracted in phenol-chloroform, precipitated in 100% ethanol, air dried, and quantitated by spectrophotometry. DNA PCR was performed with final reaction concentrations of 2.5 mM MgCl 2 ; 50 mM KCl; 10 mM Tris-HCl (pH 8.3); 200 mM each of dATP, dCTP, and dGTP; 190 mM of dTTP; 10 mM of digoxigenin (DIG)-labeled dUTP; 1 U of Taq DNA polymerase (Boehringer Mannheim); 0.5 mM each of primers SK38 and SK39 specific for the gag region of the HIV-1 genome [24] ; 250 copies of HIV mimic DNA containing SK38 and SK39 binding sites with a longer internal sequence; and 0.4 mg of sample DNA in a 40-mL volume. PCR was done (GeneAmp 9600 system; Perkin Elmer, Norwalk, CT) by use of the hot start technique of denaturation at 95ЊC for 5 min followed by 35 cycles of 95ЊC for 15 s and 60ЊC for 60 s, with a final extension of 72ЊC for 7 min. To generate a standard curve, we included 10, 100, 1000, 10,000, and 100,000 copies of HIV-1 DNA in human placental DNA in each PCR assay.
For quantitative RNA PCR, the cellular and cell-free CVL samples stored in Tri reagent were melted to 4ЊC. Negative and positive controls for RNA extraction were HIV-negative CVL stored in Tri reagent alone or spiked with 0, 100, 1000, 10,000, or 100,000 recombinant moloney murine leukemia virus (MMLV) particles containing an HIV-1 gag fragment with a deletion (NIH AIDS Repository) and processed along with the patient samples. RNA was isolated with chloroform and precipitated in isopropanol. The RNA was dried, dissolved in 20 mL of diethylpyrocarbonate-treated water, and quantitated by spectrophotometry. For RT-PCR, 5 mL of the sample was reverse-transcribed in a 10-mL reaction containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 3.75 mM MgCl 2 , 200 mM of each dNTP, 10 U of RNAase inhibitor, 25 U of MMLV reverse transcriptase, and 2.5 mM of SK39 and incubated at 22ЊC for 10 min, 42ЊC for 30 min, and 99ЊC for 5 min. The samples were then kept at 4ЊC. PCR reagent mix (40 mL) was added to each tube, and PCR was performed as described above.
DNA and RNA PCR products were quantitated by use of 0.25-, 1-, and 10-mL aliquots of the DIG-labeled PCR product with an ELISA detection kit (Boehringer Mannheim). The 10-and 0.25-mL PCR products were hybridized with a biotin-labeled SK19 probe, and the 1-mL PCR product was hybridized with a biotinlabeled internal control probe. The hybridized PCR products were transferred to a streptavidin-coated microtiter plate and incubated at 56ЊC for 3 h on a rocking platform. After the plates were washed, 200 mL of horseradish peroxidase-conjugated anti-DIG antibody was added to each well and incubated at 37ЊC for 30 min, the plates were washed again, and absorbance was read at 405 nm after 20 min of incubation in substrate solution. Two standard curves were generated, using the 10-mL PCR product aliquot for low copy number calculations and the 0.25-mL PCR product aliquot for high copy number calculations. The initial HIV-1 DNA or RNA copy number in each sample was determined by plotting its HIV-tointernal control optical density ratio, using the standard curve.
Sensitivity of the DNA PCR was 10 copies/mg of DNA, and that of the RNA PCR was 25 copies/input sample. Results were expressed as copies per CVL sample for HIV-1 DNA and cell-associated RNA PCR and as copies/mL CVL for cell-free RNA PCR. HTA. DNA extracts of all CVL samples testing positive for gag HIV-1 DNA were assessed for HIV-1 env genetic diversity, as were the PBMC samples from 5 patients that were obtained at the same time point as the CVL. The HIV-1 env gene was amplified by use of a nested PCR procedure, described elsewhere [25] . Firstround primers ED5 and ED12 (corresponding to positions 6556-6581 and 7822-7792 of GenBank HIV1-HXB2 genome) and second-round primers ES7 and ES8 (corresponding to the complement of the M13 forward and reverse sequencing primers followed by positions 6579-6598 and 7225-7245, respectively) generated a 627-bp target-dependent fragment spanning regions C3-V5 of the gp120 coding sequence. This nested PCR procedure had a sensitivity of 1 copy of HIV-1 per 1 mg of genomic DNA.
Duplicate serial 2-fold dilutions were performed on each sample to a PCR-negative end point. The amount at the negative end point (in mg) was then used to calculate the amount of input DNA needed for у30 copies of HIV-1 template, and this PCR product was used for heteroduplex analysis. At least 30 copies of template yields a representative picture of the virus pool, giving a probability of ∼90% of detecting a variant comprising 5% of the virus population. When the amount of DNA extract required for 30 copies of template was more than that available for PCR, the entire sample was analyzed using pooled amplified DNA from multiple individual PCR reactions (this was done for the CVL samples from 2 subjects who transmitted and 3 subjects who did not transmit HIV-1 perinatally). If the initial PCR was negative, the PCR was repeated at a decreased annealing temperature for the first 5 cycles to allow for less stringent priming. If this PCR was negative, the sample was not included in HTA analysis. The number of HIV-1 env DNA copies per sample correlated with the number of HIV-1 gag copies per sample calculated by different quantitation methods (r = s , , Spearman's rank order correlation). 0.72 P ! .01
Each PCR product was radioactively labeled by incorporating a - 32 TTP, then mixed in a 1 : 100 ratio with unlabeled product in the presence of a high salt buffer to inhibit Taq polymerase [25] . The mixture was heated at 94ЊC for 2 min, then rapidly cooled on wet ice to force the formation of heteroduplexes. The sample was electrophoresed in a 5% polyacrylamide gel on a V16 vertical gel apparatus (Gibco/BRL, Gaithersburg, MD) for 3 h at 250 V, dried on a gel dryer (Bio-Rad, Hercules, CA), and developed by autoradiography for 12-24 h. Heteroduplexes appeared as slow-migrating bands or smearlike patterns, with migration distance inversely proportional to the degree of genetic dissimilarity in the heteroduplex and band sharpness depending on the extent of HIV-1 env genetic complexity in the sample [25, 26] . In contrast, the perfectly matched homoduplexes appeared as fast-migrating bands at the bottom of the gel. This assay can detect у2% genetic divergence of mismatched base pairs and insertions or deletions of 1-3 bp [26] .
The extent of genetic diversity within each sample was inferred from the migration distances between the homoduplex and heteroduplex bands on the gel, where relative mobility equals the distance from the bottom of the loading well to the midpoint of the heteroduplex bands minus the distance from the bottom of the loading well to the midpoint of the homoduplex bands. The gels were visually inspected and assessed to see if the heteroduplex pattern resembled 1 homoduplex band of у2 variants. When CVL and paired PBMC samples were compared, the extent of genetic diversity between samples was assessed by observing a shift in the heteroduplex pattern in the CVL sample in comparison with its corresponding PBMC sample, using the CVL sample as the radioactive probe for both samples.
Statistical analysis. Groups were compared using Fisher's exact test for proportions, t tests for normally distributed data, and the Mann-Whitney rank sum test for nonparametric comparisons.
Spearman's rank order correlation and McNemar's exact test were used to assess correlations when appropriate. All P values presented are from 2-tailed tests. The small sample size of the data set precluded useful investigation of the factors affecting perinatal HIV-1 transmission by logistic regression modeling. In the CVL samples, 9 (41%) of 22 yielded culturable HIV-1, 16 (67%) of 24 were PCR positive for proviral HIV-1 DNA, 7 (30%) of 23 were positive for cell-free HIV-1 RNA, and 11 (45%) of 24 were positive for cell-associated HIV-1 RNA. Peripheral CD4 cell counts did not correlate with levels of HIV-1 in the CVL by DNA or RNA PCR or by amount of genital tract inflammation, as measured by numbers of PMNL or macrophages in the CVL. Within each CVL specimen, levels of cellfree and cell-associated RNA were positively correlated (r = , ; Spearman's rank order correlation). 0.48 P = .03 There were several differences between transmitters and nontransmitters with respect to immunosuppression and genital tract virus load (table 1) . Transmitters had significantly fewer peripheral CD4 cells than nontransmitters: 57% of transmitters and 7% of nontransmitters had !200 CD4 cells/mm 3 ( , P = .02 Fisher's exact test). Transmitters had significantly higher HIV-1 load in their blood, as measured by quantitative PBMC culture. HIV-1 shedding in the genital tracts of transmitters was more frequent and had higher copy numbers, as measured by HIV-1 culture, DNA PCR, or cell-free RNA PCR of the CVL. There was no difference in the frequency or amount of genital tract shedding of cell-associated HIV-1 RNA between transmitters and nontransmitters. Numbers of PMNL or macrophages in the CVL did not differ between transmitters and nontransmitters.
Results

Of
Comparison of subjects who shed proviral HIV-1 DNA in the genital tract with those who did not revealed significant virologic and immunologic differences (table 2). Although peripheral CD4 cell counts did not differ between the 2 groups, PBMC virus load was significantly higher in subjects who shed HIV-1 proviral DNA in CVL. Both presence and amount of cell-free HIV-1 RNA were higher in women who shed HIV-1 proviral DNA in the CVL. All 7 (100%) patients PCR positive for cell-free HIV-1 RNA and 10 (91%) of 11 PCR positive for cell-associated RNA were also PCR positive for HIV-1 proviral DNA in the CVL. Inflammation, as measured by number of PMNL in CVLs, was significantly higher in women with detectable proviral HIV-1 DNA in the genital tract. Within CVL samples, quantity of HIV-1 proviral DNA was significantly correlated with number of PMNL per CVL sample ( , r = 0.58 ) and amounts of cell-associated HIV-1 RNA ( P = .01 r = , ) and cell-free HIV-1 RNA ( , ; 0.47 P = .03 r = 0.45 P = .05 Spearman's rank order correlation).
When we examined HIV-1 DNA PCR-positive CVLs by HTA, transmitters usually had lower heteroduplex mobilities, indicating that they had more env genetic diversity in CVL than did nontransmitters (figure 1). The relative mobility value approached zero with a more diverse population of env PCR product and heteroduplexes that were migrating more slowly and approached or equaled one with a homogeneous population of env PCR product and homoduplexes that were migrating more quickly. When the gels were inspected and the number of variants was estimated from the HTA pattern, there was a trend toward more variants in the transmitting group, with 6 (86%) of 7 transmitters and 3 (33%) of 9 nontransmitters having у2 variants in the peripartum CVL sample ( , Fisher's exact P = .06 test). Among the CVL samples, the amount of proviral HIV-1 DNA inversely correlated with the relative mobility of the sample on HTA analysis ( , ; Spearman's rank r = 0.60 P = .04 order correlation). There was no correlation between relative mobility and either HIV-1 RNA level or amount of genital tract inflammation in the CVL.
HIV-1 env diversity between PBMC and CVL samples taken at the same time point was evaluated among 5 patients. In the 3 transmitters, there was a shift in relative mobility of when the labeled CVL sample was used as a probe 0.15 ‫ע‬ 0.17 and tracked against PBMC and compared with labeled CVL probe tracked against itself. In the 2 nontransmitters, there was no shift in the relative mobility when PBMC underwent HTA in a similar manner ( figure 2 ).
Discussion
This study demonstrated an increase in presence and amount of proviral and cell-free HIV-1 in genital tract secretions of women who transmitted HIV-1 perinatally. In pregnant women who shed HIV-1 into the genital tract, those who transmitted virus to their infants had a greater diversity of HIV variants in CVL specimens than did nontransmitters. The amount of HIV-1 DNA significantly correlated with extent of inflammation and amount of HIV-1 RNA in the CVL, regardless of transmission status. Genital tract infection or inflammation has been associated with increased HIV-1 DNA shedding from the cervix in both pregnant and nonpregnant women [27, 28] . Although the relatively few women in the present study limited statistical comparison, the results nevertheless are in concordance with previous studies. It is notable that, although increased PMNL in the CVL correlated with amount of HIV-1 DNA shed in the genital tract, there was no difference in genital tract inflammation, as measured by either PMNL or macrophages, between transmitters and nontransmitters. This may be explained both by the few subjects and by the large range of values for PMNL and macrophages, precluding a finding of statistical significance in this data set. Further investigation of these parameters is warranted in larger populations. Taken together, these studies suggest that the female genital tract is a dynamic milieu in which local immune activation in response to infection or inflammation may transactivate latently infected mucosal lymphocytes and macrophages, resulting in increased HIV-1 shedding in the birth canal [29] .
This study demonstrated a significant association between presence of vaginal candidiasis and perinatal transmission. It is doubtful that vaginal candidiasis per se is a factor in acquisition of HIV-1 in the birth canal, but it is probably a marker of advancing HIV-1 disease and decreasing cell-mediated immunity. A multicenter study of the WITS cohort [30] also found lower CD4 cell counts to be significantly associated with vaginal candidiasis during pregnancy, and, although vaginal candidiasis was not associated with perinatal HIV-1 transmission, clinical vaginitis or vaginosis at the last antepartum visit was associated with perinatal HIV-1 transmission. This larger study suggests that abnormalities of the vaginal microbiologic milieu may be related to increased HIV-1 load in the genital tract via inflammatory mediators. In the present study, vaginal candidiasis was not present during the acquisition of the CVL samples under study and should not have had a significant effect on the number of PMNL or macrophages in the samples. The lack of candidiasis at the time of CVL sample acquisition prevents any basis on which to suggest that candidiasis influenced CVL inflammatory parameters or that treatment of this disorder may affect perinatal transmission of HIV-1.
We found a significant relationship between the shedding of HIV-1 proviral DNA and HIV-1 RNA in the genital tracts of parturient women. This concordance between coshedding of proviral DNA and HIV-1 RNA is in agreement with a previous study of 43 pregnant women and suggests that coshedding of cell-associated and cell-free HIV-1 in the genital tract occurs [28] . The present study also demonstrated a significant correlation between quantity of cell-associated and cell-free HIV-1 within CVL samples; similar findings have been described in nonpregnant women without genital tract infection [31] . The presence of inflammation in the genital tract in our study was most closely linked to detection of proviral HIV-1 DNA, which is exclusively cell associated. This finding could explain the lack of correlation between presence of HIV-1 RNA in blood and HIV-1 in CVL, as demonstrated by Rasheed et al. [32] , since the factors that influence blood HIV-1 load may differ from mucosal factors that result in HIV-1 shedding in the genital tract. Although the relative importance of cell-associated versus cell-free HIV-1 in perinatal transmission remains a subject of debate, the local and systemic factors that promote HIV-1 shedding in the genital tract may do so through migration of latently infected cells and/or their local activation, leading to de novo production of virus.
Previous studies have shown both a significant correlation [31] and a lack of correlation between amount of HIV-1 RNA in blood and cell-free HIV-1 RNA in CVL [32] . Most studies, including the present one, indicate an increased risk of transmission associated with high levels of cell-associated or cellfree HIV-1 levels in maternal blood [33] [34] [35] [36] [37] . This large body of previous work suggests that the shedding of HIV-1 DNA and RNA in the genital tract is linked, may not always be reflective of HIV-1 load in the blood, and may represent local viral , t test). P = .02 Subjects 6 (transmitter) and 11 (nontransmitter) had HIV-1 seroconversion during pregnancy.
replication in response to mucosally mediated inflammatory responses.
Higher HIV-1 diversity in the birth canal may increase the chance that a transmissible variant will be presented to the target cells of the fetal mucosa. This concept is supported by studies that showed that HIV-positive parturients who practiced unprotected intercourse during pregnancy were 14 times more likely to transmit HIV-1 to their infants than women who had no unprotected intercourse during pregnancy [38, 39] , suggesting that either genital tract inflammation or exposure to exogenous HIV-1 variants may increase the risk of HIV-1 transmission. A study of the effect of vaginal cleansing of the birth canal supports this hypothesis, showing that it had a significant impact on perinatal transmission only in the presence of prolonged rupture of membranes [40] . Cleansing may remove HIV-1 in the birth canal introduced by maternal blood or local inflammatory factors from membrane rupture.
Other studies show that elective cesarean section further decreases perinatal transmission in mothers pretreated with zidovudine, although genital tract inflammation is associated with increased perinatal transmission in women who are not treated with zidovudine [13, 41] . These data suggest that antiretroviral drugs can decrease the contributory effect of blood virus load on perinatal transmission, but local genital factors remain important to some degree.
Some HIV-1 variants may possess a selective advantage for either more efficient transmission or escape from the immune surveillance in the mother or infant. Syncytium-inducing phenotype [42] , common characteristics in N-linked glycosylation sites of the env gene [43] , inhibition or enhancement of infection by maternal IgG directed against the env protein [44] [45] [46] , and presence of the CCR5D32 coreceptor gene mutation in the infant [47, 48] have all been proven or debated as significant factors in perinatal HIV-1 transmission. Indeed, it is most likely that the etiology of perinatal HIV-1 transmission is multifactorial and that a complex interaction between viral tropism, maternal immunity, and fetal susceptibility determines the risk of perinatal transmission.
Although we were not able to assess the composition of the genital tract HIV-1 variant population exactly at the time of transmission, use of HTA in this study provided an indicator of the extent to which HIV-1 env variation may be present in the CVL at the time of highest risk for perinatal transmission. It is of particular interest that higher amounts of proviral HIV-1 correlated with higher HIV-1 env diversity in the genital tract, as demonstrated by a significant inverse correlation between amount of HIV-1 proviral DNA and relative mobility of the HIV-1 env PCR product by HTA assay. Work in progress involves comparison of the newborns' cell-associated and cellfree HIV-1 env quasispecies with that in the mothers' blood and genital tract compartments to clarify the relative importance of HIV-1 env diversity in the genital tract at parturition as it pertains to risk for perinatal HIV-1 transmission and the type of variants transmitted.
In studies of HIV-1 env evolution in the blood compartment, the highest HIV-1 diversity was associated with slowly progressing HIV-1 disease, relatively preserved CD4 cells, and low virus loads, suggesting that immune-mediated selection pres- sure is a factor in the development of higher quasispecies diversity [18] . In comparison, our study showed that HIV-1 quasispecies diversity, genital tract HIV-1 proviral DNA load, and genital tract inflammation were interrelated, but not particularly associated, with peripheral CD4 cell count. In addition, in 3 transmitters with paired CVL and blood samples, we observed that the HIV-1 env variant population tended to differ between the CVL and blood compartments. Differences in HIV-1 env between the blood and genital compartments of male and female patients have been demonstrated by conventional sequencing methods [49, 50] . These observations underscore the possibility that therapeutic approaches to decreasing HIV-1 load in the blood and genital tract must be targeted at specific mechanisms unique to each respective compartment.
The HTA method used for analysis of HIV env diversity within and between specimens is widely used to study HIV-1 genetic relationships in cases of heterosexual transmission, perinatal transmission, and transmission in the health care setting. Compared with sequencing methods, the simultaneous analysis of a higher number of proviral variants per sample by the HTA method allows a better representation of the variants in each analyzed specimen. The issue of resampling has been raised with respect to the danger of underestimation of quasispecies diversity if clones are derived from PCR products of specimens that originally had a low number of variants [51] . In our study, we attempted to avert the issue of low virus load and underestimation of quasispecies diversity by estimation of copy number by end-point dilution and including the amount of template DNA to represent ∼30 proviral HIV-1 copies in the original sample. Still, HIV-1 provirus load correlated with amount of HIV-1 env diversity in our study, suggesting that the factors that determine the extent of HIV-1 provirus shedding and env diversity are closely linked.
Although all subjects in our study received zidovudine therapy in the third trimester, the high rate (29%) of HIV-1 perinatal transmission in this data set does not agree with the largest prospective, randomized study addressing this question, ACTG 076 [52] . This relatively high rate of transmission despite antiretroviral therapy probably represented sampling bias in our group of subjects, if women at higher risk for HIV perinatal transmission were more likely to present for examination in the peripartum period or otherwise were more likely to have CVL specimens available for analysis. Recent data suggest that shorter courses of zidovudine than those administered by the ACTG 076 protocol offer significant protection from perinatal transmission [53] . These studies underscore the importance of exposure of the infant to maternal virus at the time of delivery. Whether genital tract HIV-1 load or diversity is significantly decreased with peripartum antiretroviral therapy remains to be investigated, although a decrease in HIV-1 RNA in the CVLs of nonpregnant subjects after the initiation of antiretroviral therapy has been demonstrated [31] .
These findings may provide justification to pursue the development of antiretroviral and immune-modulating strategies directly aimed at decreasing HIV-1 load and inflammation in the birth canal at the time of delivery. Aggressive treatment of inflammatory and infectious diseases of the genital tract during pregnancy and more intensive investigation of the effect of combination antiretroviral therapy on genital tract HIV-1 load are warranted.
